Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million

02:20

Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock

Full story

Debug: backend attempts

http://api:8080/v1/feed/items/c621854b-f259-4d4f-af23-d03c49855d49?tenant_id=047dc75b-5cff-41f7-b49d-b10cc76161ad&language_code=te — 200

{"requested_language":"te","item":{"id":"c621854b-f259-4d4f-af23-d03c49855d49","slug":"zydus-lifesciences-arm-to-acquire-us-oncology-firm-assertio-for-166-million-c621854b","category":"top-stories","published_at":"2026-05-14T02:20:03Z","title":"Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million","summary":"Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock","source_url":"https://www.thehindu.com/business/Industry/zydus-lifesciences-arm-to-acquire-us-oncology-firm-assertio-for-166-million/article70976775.ece","source_name":"www.thehindu.com","image_url":"https://th-i.thgim.com/public/incoming/ct2phu/article70976817.ece/alternates/LANDSCAPE_1200/iStock-1354172444.jpg","served_language":"en","is_fallback":true,"available_languages":["en"]}}